Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02718833Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2016
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Primary endpoints: Overall Response Rate at 2 years and Treatment-Related Adverse Events at 2 years. Started Jun 2016; status: active, not recruiting.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02718833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718833.